


Data Sheet

Product Name:	Ranirestat
Cat. No.:	CS-4282
CAS No.:	147254-64-6
Molecular Formula:	C ₁₇ H ₁₁ BrFN ₃ O ₄
Molecular Weight:	420.19
Target:	Aldose Reductase
Pathway:	Metabolic Enzyme/Protease
Solubility:	DMSO : ≥ 50 mg/mL (118.99 mM)



BIOLOGICAL ACTIVITY:

Ranirestat (AS-3201) is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy.

References:

- [1]. Kurono M, et al. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability. *Biochem Pharmacol.* 2006 Jan 12;71(3):338-53.
- [2]. Matsumoto T, et al. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux. *J Pharmacol Sci.* 2009 Feb;109(2):203-10.
- [3]. Toyoda F, et al. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats. *J Diabetes Res.* 2014;2014:672590.

CAIndexNames:

Spiro[pyrrolidine-3,4'(1'H)-pyrrolo[1,2-a]pyrazine]-1',2,3',5(2'H)-tetrone, 2'-[(4-bromo-2-fluorophenyl)methyl]-, (3R)-

SMILES:

O=C(N1CC2=CC=C(Br)C=C2F)C3=CC=CN3[C@]4(C(NC(C4)=O)=O)C1=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA